Compare Philip Morris International Inc. (PM) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Philip Morris International Inc. vs Summit Therapeutics Inc — how do they compare? Philip Morris International Inc. trades at $195 (market cap $293.07B), while Summit Therapeutics Inc trades at $14.78 (market cap $11.34B). The key difference: Philip Morris International Inc. is far larger — about 25.8× Summit Therapeutics Inc's market cap, and Philip Morris International Inc. pays a 3.13% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PM | SMMT | |
|---|---|---|
Market Cap | $293.07B | $11.34B |
Sector | Consumer Staples | Health |
52-Week High | $192.98 | $29.32 |
52-Week Low | $144.33 | $13.05 |
Enterprise Value | $339.57B | $10.76B |
Dividend Yield | 3.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Philip Morris International (PM) trades at $194.30, up 0.82% today, with strong analyst support (68% buy ratings) and a consensus price target of $194. The stock shows bullish technical momentum above key support levels, supported by robust fundamentals including 2025 revenue of $40.65B and net income of $11.35B. Recent news highlights include a $500M impairment charge and updated 2026 guidance, while the IQOS brand gained recognition as a top global brand.
PM offers stable dividend income and growth potential, but faces headwinds from cost pressures, currency volatility, and regulatory risks in tobacco markets. The current valuation at 26.47 P/E appears reasonable given earnings consistency, though investors should monitor margin trends and illicit market impacts in Europe. Near-term price action hinges on Q2 2026 earnings versus the $2.04 EPS estimate.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
